Soligenix SNGXW 深 沪
等待开盘 06-25 09:30:00 美东时间
0.009
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.009
- 总市值 36.02万
- 52周最高 0.82
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.008
- 委 比 0.00%
- 总股本 4002.05万
- 历史最高 1.314
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Soligenix Halts HyBryte Program, Refocuses Pipeline Strategy
Soligenix ( ($SNGX) ) just unveiled an update. On June 10, 2026, Soligenix rece...
06-13 05:05
Soligenix To Apply For Bundibugyo Ebola Vaccine Development Funding
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted
06-08 19:34
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development PRINCETON, N.J., June 8, 2026 /PRNewswire/ -- Soligenix, ...
06-08 19:30
Soligenix Expands At-The-Market Equity Financing Capacity
Soligenix ( ($SNGX) ) has issued an announcement. On May 28, 2026, Soligenix, I...
05-29 07:15
Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.
05-27 17:10
Soligenix says ThermoVax platform supports rapid development of thermostable Bundibugyo virus vaccine
Soligenix says ThermoVax platform supports rapid development of thermostable Bundibugyo virus vaccine Soligenix flagged its ThermoVax platform as a rapid starting point for a new Bundibugyo virus vaccine in response to the Congo outbreak. Preclinical work was already presented as supportive evidence
05-26 19:32
Soligenix GAAP EPS of $0.28
Soligenix press release (SNGX): Q1 GAAP EPS of $0.28. Research and development expenses were $1.8 million as compared to $1.9 million for the quarter ended March 31, 2026 and 2025, respectively. The d...
05-08 19:44
Soligenix Q1 net loss narrows on lower expenses
Soligenix Q1 net loss narrows on lower expenses Overview US biopharma firm's Q1 net loss narrowed due to lower operating expenses Company reported no revenue for Q1 2026 Phase 3 FLASH2 trial for HyBryte in CTCL halted for futility after interim analysis Outlook Company is analyzing FLASH2 trial data
05-08 19:39
Soligenix Q1 EPS $(0.28), Inline
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 73.58 percent increase over losses of $(1.06) per share from the same period last year.
05-08 19:38
